enGene Holdings Inc. (ENGN)

Market Cap	341.54M
Revenue (ttm)	n/a
Net Income (ttm)	-55.14M
Shares Out	50.98M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,824
Open	7.10
Previous Close	7.10
Day's Range	6.60 - 7.40
52-Week Range	4.42 - 18.40
Beta	-0.65
Analysts	Strong Buy
Price Target	29.78 (+344.48%)
Earnings Date	Mar 10, 2025

About ENGN

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: ENGN
• Website: https://www.engene.com

Analyst Forecast

According to 9 analysts, the average rating for ENGN stock is "Strong Buy." The 12-month stock price forecast is $29.78, which is an increase of 344.48% from the latest price.

Price Target

$29.78

(344.48% upside)

Analyst Consensus: Strong Buy